Result of AGM

RNS Number : 0534Q

Tissue Regenix Group PLC

12 June 2015

 



Tissue Regenix Group Plc

("Tissue Regenix" or "the Company")

Result of AGM

YORK, 12 June, 2015 - Tissue Regenix Group plc (AIM:TRX), the regenerative medical devices company, hereby provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.

For Further Information

Tissue Regenix Group Plc:                                                           [phone]

Antony Odell

Ian Jefferson

Jefferies International Ltd:                                                         [phone]

Simon Hardy

Harry Nicholas

Tulchan Communications:                                                           [phone]

Tom Buchanan                                                                                 

Victoria Huxster                                                                              

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

RAGSFEFFEFISELM